SPHS Sophiris Bio, Inc.

2.47
-0.02  -1%
Previous Close 2.49
Open 2.47
Price To book 5.23
Market Cap 74.37M
Shares 30,111,000
Volume 172,903
Short Ratio 5.55
Av. Daily Volume 356,006

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b six-month biopsy data for all patients in 1Q 2018 with final biopsy data due 4Q 2018.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer
  2. SPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon
  3. Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights
  4. Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting
  5. Sophiris Bio to Present at 16th Annual Needham Healthcare Conference
  6. SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway
  7. Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights
  8. Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress
  9. Sophiris Bio to Present at 29th Annual ROTH Conference
  10. Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference
  11. Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
  12. Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  13. Three Biotech Companies With Large Upside Potential
  14. Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
  15. Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital
  16. SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions
  17. 5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside